VivoSeq
Hematology

Allogeneic Hematopoietic Stem Cell Transplantation

0

Pipeline Programs↗

19

Active Trials↗

5

Companies Involved↗

Allogeneic Hematopoietic Stem Cell Transplantation is an early-stage landscape with 0 programs across 5 companies. The most active players are Takeda, Sanofi, Roche.

Intelligence

Pipeline Metrics

Competitive Density

35/100

Pipeline Velocity

22/100

Mech. Concentration

N/A

Completion Rate

57/100

Attrition Rate

26/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Takeda logo

Takeda

0 programs

PreclinicalSanofi logo

Sanofi

0 programs

PreclinicalRoche logo

Roche

0 programs

PreclinicalMerck & Co. logo

Merck & Co.

0 programs

PreclinicalH

Hebei Senlang Biotechnology Inc., Ltd.

0 programs

Preclinical

Pipeline

Programs by Phase

No pipeline programs currently tracked for this disease.

Analysis

Trial Status

70

clinical trials

Completed24 · 34%
Terminated15 · 21%
Recruiting13 · 19%
Unknown status9 · 13%
Not yet recruiting5 · 7%
Withdrawn3 · 4%
Other1 · 1%

Clinical Trials

Trial Activity

70 trials

Improved Myeloablative Allogeneic Hematopoietic Stem Cell Transplantation Protocol for the Treatment of Epstein Barr Virus T/NK Lymphoproliferative Disease (EBV-T/NK LPD) and Prevention of Post Transplant Graft-versus-host Disease
Recruiting·—·Phase 4·NCT07029958·48 enrolled
Human Leukocyte Antigen (HLA) Mismatched Unrelated Allogeneic Hematopoietic Stem Cell Transplantation
Recruiting·—·Phase 1·NCT06809712·29 enrolled
Risk-ADAPTed Conditioning Regimen for Allogeneic Hematopoietic Stem Cell Transplantation
Recruiting·UUniversity of California, Irvine·Phase 2·NCT06028828·60 enrolled
Molecular Genetics Guide the Maintenance Therapy After Allogeneic Hematopoietic Stem Cell Transplantation
Recruiting·RRuijin Hospital·Phase 2/3·NCT06972641·126 enrolled
Immunoglobiulin-specific Prophylaxis of Citomegalovirus Infections in Immunocompromised Children Undergoing Allogeneic Hematopoietic Stem Cell Transplantation
Recruiting·—·N/A·NCT07013370·150 enrolled
Efficacy and Safety of Lusutrombopag After Allogeneic Hematopoietic Stem Cell Transplantation
Recruiting·TThe General Hospital of Western Theater Command·N/A·NCT07483385·45 enrolled
Determination of Factors Involved in the Regulation of Immune Responses After Allogeneic Hematopoietic Stem Cell Transplantation
Recruiting·—·N/A·NCT03357172·700 enrolled
Human Leukocyte Antigen (HLA) Mismatched Related Allogeneic Hematopoietic Stem Cell Transplantation
Recruiting·—·Phase 1·NCT06809699·29 enrolled
Fludarabine Plus Melphalan Versus Addition of Venetoclax to Fludarabine/Melphalan Conditioning Regimen for Allogeneic Hematopoietic Stem Cell Transplantation in AML/MDS Patients Aged > 50 Years: a Multicenter, Randomized, Phase 3 Trial
Recruiting·FFirst Affiliated Hospital of Zhejiang University·Phase 3·NCT07396480·186 enrolled
A Phase I-II Study of High-Dose Post-Transplant Cyclophosphamide, Bortezomib, and Abatacept for the Prevention of Graft-Versus-Host Disease (GVHD) Following Allogeneic Hematopoietic Stem Cell Transplantation (HSCT)
Recruiting·NNorthwell Health·Phase 1/2·NCT06681922·10 enrolled
Co-infusion of Treg-enriched Donor Lymphocytes With CD3-depleted Hematopoietic Stem Cell Graft to Prevent Graft-versus Host Disease After Allogeneic Hematopoietic Stem Cell Transplantation Among Children With Hematologic Malignancies
Recruiting·FFederal Research Institute of Pediatric Hematology, Oncology and Immunology·Phase 2/3·NCT07366801·64 enrolled
Exploratory Study of EBV-TCR-T Cell Injection for EBV DNAemia After Allogeneic Hematopoietic Stem Cell Transplantation
Recruiting·—·Phase 1/2·NCT07368634·18 enrolled
A Prospective Approach for the Early Detection of Infectious and Noninfectious Lung Diseases Following Allogeneic Hematopoietic Stem Cell Transplantation
Recruiting·National Heart, Lung, and Blood Institute (NHLBI)·N/A·NCT06093867·40 enrolled
Palifermin With Leuprolide Acetate for the Promotion of Immune Recovery Following Total Body Irradiation Based T-Cell Depleted Allogeneic Hematopoietic Stem Cell Transplantation
Active, not recruiting·MMemorial Sloan Kettering Cancer Center·Phase 2·NCT01746849·82 enrolled
Efficacy of the antiCD38 Monoclonal Antibody Isatuximab in the Treatment of PCRA by Major ABO Mismatch After Allogeneic Hematopoietic Stem Cell Transplantation
Not yet recruiting·AAssistance Publique - Hôpitaux de Paris·Phase 2·NCT05559827·90 enrolled
Page 1 of 5

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)